CHICAGO --A drug to prevent bone loss during breast cancer treatment also appears to substantially cut the risk that the cancer will return.The drug is called Zometa. Researchers studied 1,800 pre-menopausal women taking hormone treatments for early stage breast cancer. Findings show Zometa cut the chance that cancer would recur by one-third.
Zometa may eventually be tested against other cancers that tend to spread to bones.
This study was presented at an American Society of Clinical Oncology conference in Chicago this past weekend.